<DOC>
	<DOCNO>NCT02013297</DOCNO>
	<brief_summary>The purpose study evaluate efficacy hypofractionated stereotactic radiation treatment ( SBRT ) child , teenager young adult malignant tumor .</brief_summary>
	<brief_title>Study SBRT Efficacy Intra Extra -Cranial Tumors Metastasis Pediatrics Population ( SBRT Pediatrics )</brief_title>
	<detailed_description>SBRT ( Stereotactic Body Radiation Therapy ) radiotherapy treatment involve delivery single high dose radiation treatment fractionate radiation treatment ( usually 5 ) . A high potent biological dose radiation deliver tumor improving cure rate tumor , manner previously achievable standard conventional radiation therapy . For adult patient , `` Haute Authorité de Santé '' ( HAS ) validate indication treatment following : - Few primary secondary brain tumor , surgically remove - Spinal tumor - Primary bronchopulmonary tumor T1 T2 N0 M0 pulmonary metastasis slow growth control primary tumor . For pediatrics patient , indication validate HAS . Indications validate adult rare pediatrics exceptional , case efficient alternative treatment exist . In consequence , regard good result obtain adult patient , seem important validate efficacy treatment pediatrics population</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Spinal Cord Neoplasms</mesh_term>
	<mesh_term>Spinal Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA : 18 month ≤ age ≤ 20 year Malignant primary tumor , histologically cytologically proven Systemic disease control slow evolution Written indication SBRT accord local pediatrics meet national Radiotherapy ( RT ) web conference Performance Status ≤ 2 accord Eastern Cooperative Oncology Group ( ECOG ) Sites Brain metastasis ( ≤ 3 MRI ) suitable surgery , without hemorrhage , less 3 cm , brain stem Primary secondary spinal/para spinal metastasis ( ≤ 3 ) , suitable surgery non operable macroscopic residue , less 5 cm Lung metastasis ( ≤ 3 ) , less 5 cm , eligible surgery , macroscopic residue suitable surgery Previously irradiate relapsing isolated primitive/secondary tumor ( intra cranial extra cranial ) , possible surgery , macroscopic residue . Affiliation social security scheme Signed Informed consent patient parent . IN ADDITION FOR RELAPSING EPENDYMOMA : Histologically proven local ependymoma diagnosis Previously irradiate ependymoma Exclusive local relapse previously irradiate site Review operability time relapse multidisciplinary staff Relapse must confirm neurooncology multidisciplinary staff , MRI evolutivity characteristic Time relapse previous irradiation ≥ 1 year NONINCLUSION CRITERIA : Concomitant chemotherapy No evaluable target Pregnancy Followup impossible IN ADDITION FOR RELAPSING EPENDYMOMAS : Metastatic patient diagnosis and/or relapse Complete remission never obtain NONRANDOMIZATION DOSIMETRIC CRITERIA ( ONLY FOR EPENDYMOMA ) Cumulative dose brain stem ≥ 115 Gy Tumor volume relapse ≥ 30 cm3 Primary RT dose + Reirradiation dose 112 Gy Cumulative dose chiasma &gt; 54 Gy Cumulative dose point brain &gt; 115 Gy</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pediatrics</keyword>
	<keyword>SBRT</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>Pulmonary metastasis</keyword>
	<keyword>Spinal metastasis</keyword>
	<keyword>Pulmonary primary tumor</keyword>
	<keyword>Spinal primary tumor</keyword>
	<keyword>Relapsed ependymoma</keyword>
	<keyword>Relapsed irradiated tumor</keyword>
	<keyword>Local control rate</keyword>
	<keyword>Safety</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Progression Free Survival</keyword>
</DOC>